IFNA2 and acute myeloid leukemia: Importantly, immediate and rapid progressing disease has been described in acute lymphoblastic leukemia patients treated with lower doses of IFNα (Ochs et al. 1986) and in vitro testing of AML cells has indicated that approximately a third of the patient samples responded with increased clonogenicity when treated with lower doses IFNα (Ludwig et al. 1983).